aprepitant

Known as: aprepitant [Chemical/Ingredient], (2R)-(1R)-3,5-bis(trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine, 3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one 
A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2018
05020022018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy-induced nausea and… (More)
  • table I
  • table II
  • table III
  • table IV
  • table V
Is this relevant?
2007
2007
BACKGROUND Antiemetics currently in use are not totally effective. Neurokinin-1 receptor antagonists are a new class of… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND An early clinical trial suggested that the substance P (neurokinin(1) receptor) antagonist, aprepitant, might provide… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND We compared an aprepitant regimen with a control regimen of ondansetron + dexamethasone given for 4 days. PATIENTS… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2004
2004
The NK(1) receptor antagonist aprepitant (EMEND(R)), developed for use in combination with a 5HT(3) receptor antagonist and a… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Aprepitant is a highly selective substance P (neurokinin 1 [NK(1)] receptor) antagonist that significantly improves… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
PURPOSE In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Aprepitant is a novel neurokinin 1 (NK(1)) antagonist that has been shown to improve control of chemotherapy-induced… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND The neurokinin-1 antagonist aprepitant (EMEND; Merck Research Laboratories, West Point, PA) has been shown to reduce… (More)
Is this relevant?